Among 155 patients aged 0 to 24 months, 96.1% of episodes were food-triggered and 90.4% of epinephrine recipients received only 1 dose.
News|Articles|September 12, 2026
FAQ: Treating Fall Allergic Rhinitis Under The 2026 ARIA-EAACI Update
Author(s)Chelsie Derman
Fact checked by: Tim Smith
As ragweed and mold drive this year's fall symptom surge, updated GRADE recommendations shift first-line therapy toward combination intranasal treatment.
Advertisement
Advertisement
Ragweed, mold, and lingering warm temperatures are driving this year's
Related to this article
In the phase 3 RAPIDe-3 trial published in The Lancet, median time to symptom relief was 1.28 hours with deucrictibant vs more than 12 hours with placebo.
With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.
Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.
A roundup of highlights from EADV Congress 2026 in Vienna, spanning dupilumab real-world data, pipeline biologics, and a first-in-class oral agent.
In a LIBERTY post hoc analysis, most patients restarting infliximab as SC 240 mg after a drug holiday had prior ADAs, yet outcomes were similar.
US claims data from Fall Clinical 2026 suggest hidradenitis suppurativa symptoms occur at similar rates in both sexes, hinting at underdiagnosis in males.
At the standard 100 ng/mL threshold, FIT detected 62.0% of colorectal cancers in women vs 77.4% in men, with proximal tumors driving much of the gap.
Advertisement
Advertisement